---
layout: post
title: New Drug Approvals 2013 - Pt. IX - Dabrafenib mesylate (Tafinlar®)
date: '2013-06-04T10:06:00.000+01:00'
author: Bissan Al-Lazikani
tags:
- Small Molecule Drugs
- 2013 New Drugs
- Kinase inhibitor
modified_time: '2013-06-22T08:12:36.561+01:00'
thumbnail: http://3.bp.blogspot.com/-5oYoW5Sa52M/Ua1el9c0deI/AAAAAAAAAMs/VDOn5QZXWnE/s72-c/braf3d.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-8786209297627590701
blogger_orig_url: http://chembl.blogspot.com/2013/06/new-drug-approvals-2013-pt-ix.html
---

<center>
<br />
<img nbsp="" src="https://www.ebi.ac.uk/chembltools/autoiconlarge2/1,0,0,2,0,1,0,0,0,1" width="400" /><br />
<b><br />
</b></center>
<center>
<b>ATC code:</b> L01XE15<br />
<b>Wikipedia:</b> <a href="http://en.wikipedia.org/wiki/Dabrafenib">Dabrafenib</a><br />
<br />
</center>
<br />
On May 29th 2013 the FDA approved dabrafenib mesylate (trade name: Tafinlar®, research codes GSK-2118436A and GSK-2118436B) for the treatment of patients with unresectable metastatic melanoma harbouring the BRAF V600E mutation. In clinical trials, dabrafenib showed improved progression-free survival (PFS) over the comparator dacarbazine (median PFS 5.1 months for&nbsp;dabrafenib compared to 2.7 months for&nbsp;dacarbazine). Moreover, in a multicentre open-label Phase II trial&nbsp;dabrafenib showed effectiveness on brain metastases of melanoma regardless of whether the patients had been previously treated.<br />
<br />
As with the previously approved BRAF inhibitor, vemurafenib, the major side effect of&nbsp;dabrafenib is the emergence of malignant cutaneous&nbsp;squamous cell carcinomas and keratoacanthomas.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://3.bp.blogspot.com/-5oYoW5Sa52M/Ua1el9c0deI/AAAAAAAAAMs/VDOn5QZXWnE/s1600/braf3d.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="200" src="http://3.bp.blogspot.com/-5oYoW5Sa52M/Ua1el9c0deI/AAAAAAAAAMs/VDOn5QZXWnE/s200/braf3d.png" width="155" /></a></div>
<br />
The main molecular target for dabrafenib is the human mutant serine/threonine kinase, BRAF (Uniprot for wild type protein: <a href="http://www.uniprot.org/uniprot/P15056">P15056</a>). Dabrafenib potently&nbsp;inhibits multiple mutant BRAF species including V600E at 0.65 nM, V600K at 0.5 nM and V600D at 1.84 nM. It also inhibits wild type BRAF at 3.2 nM and wild type CRAF at 5 nM.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://4.bp.blogspot.com/-p-Iur4mlLLM/Ua1aJoPaeDI/AAAAAAAAAMY/4KOV1CTtOJU/s1600/Dabrafenib.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="200" src="http://4.bp.blogspot.com/-p-Iur4mlLLM/Ua1aJoPaeDI/AAAAAAAAAMY/4KOV1CTtOJU/s200/Dabrafenib.png" width="167" /></a></div>
<br />
Dabrafenib is administered orally as capsules containing the dabrafenib mesylate salt. Dabrafenib freebase (ChEMBL:<a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2028663">CHEMBL2028663</a>) has a molecular weight of 519.6 and AlogP of 5.38.&nbsp;The molecular formula of dabrafenib is&nbsp;C23H20F3N5O2S2.&nbsp;After oral administration, the median time to reach peak plasma concentration (Tmax) is 2 hours; the mean absolute bioavailability is 95% and the mean terminal half-life is 8 hours after oral administration.<br />
<br />
Tafinlar®&nbsp;is produced by <a href="http://www.gsk.com/media/press-releases/2013/two-new-gsk-oral-oncology-treatments--braf-inhibitor-tafinlar---.html">Glaxosmithkline</a><br />
<br />
The full Prescribing Information is <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202806s000lbl.pdf">here</a><br />
<br />
bissan